DK3724190T3 - Substituerede bicykliske heterocykliske forbindelser som PRMT5 inhibitorer - Google Patents

Substituerede bicykliske heterocykliske forbindelser som PRMT5 inhibitorer Download PDF

Info

Publication number
DK3724190T3
DK3724190T3 DK18836520.9T DK18836520T DK3724190T3 DK 3724190 T3 DK3724190 T3 DK 3724190T3 DK 18836520 T DK18836520 T DK 18836520T DK 3724190 T3 DK3724190 T3 DK 3724190T3
Authority
DK
Denmark
Prior art keywords
heterocyclic compounds
bicyclic heterocyclic
substituted bicyclic
prmt5 inhibitors
prmt5
Prior art date
Application number
DK18836520.9T
Other languages
English (en)
Inventor
Prathap Sreedharan Nair
Ganesh Bhausaheb Gudade
Sachin Sethi
Dipak Raychand Lagad
Chetan Sanjay Pawar
Mahadeo Bhaskar Tryambake
Chaitanya Prabhakar Kulkarni
Anil Kashiram Hajare
Balasaheb Arjun Gore
Sanjeev Anant Kulkarni
Milind Dattatraya Sindkhedkar
Venkata P Palle
Rajender Kumar Kamboj
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Application granted granted Critical
Publication of DK3724190T3 publication Critical patent/DK3724190T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK18836520.9T 2017-12-13 2018-12-13 Substituerede bicykliske heterocykliske forbindelser som PRMT5 inhibitorer DK3724190T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN201721044886 2017-12-13
IN201821024634 2018-07-02
IN201821040029 2018-10-23
PCT/IB2018/060015 WO2019116302A1 (en) 2017-12-13 2018-12-13 Substituted bicyclic heterocyclic compounds as prmt5 inhibitors

Publications (1)

Publication Number Publication Date
DK3724190T3 true DK3724190T3 (da) 2022-10-10

Family

ID=65036860

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18836520.9T DK3724190T3 (da) 2017-12-13 2018-12-13 Substituerede bicykliske heterocykliske forbindelser som PRMT5 inhibitorer

Country Status (28)

Country Link
US (2) US11459330B2 (da)
EP (1) EP3724190B1 (da)
JP (1) JP7282778B2 (da)
KR (1) KR20200098598A (da)
CN (1) CN111712498B (da)
AU (1) AU2018385664B2 (da)
BR (1) BR112020011746A2 (da)
CA (1) CA3085259A1 (da)
CL (1) CL2020001576A1 (da)
CR (1) CR20200263A (da)
CU (1) CU24621B1 (da)
DK (1) DK3724190T3 (da)
ES (1) ES2927860T3 (da)
GE (1) GEP20227359B (da)
HR (1) HRP20221207T1 (da)
HU (1) HUE059945T2 (da)
IL (1) IL274936B2 (da)
LT (1) LT3724190T (da)
MX (1) MX2020006181A (da)
PE (1) PE20211444A1 (da)
PH (1) PH12020550881A1 (da)
PL (1) PL3724190T3 (da)
PT (1) PT3724190T (da)
RS (1) RS63623B1 (da)
SG (1) SG11202004934QA (da)
UA (1) UA126349C2 (da)
WO (1) WO2019116302A1 (da)
ZA (1) ZA202003528B (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11077101B1 (en) 2018-07-18 2021-08-03 Tango Therapeutics, Inc. Compounds and methods of use
CA3114672A1 (en) 2018-10-05 2020-04-23 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
BR112021019465A8 (pt) 2019-04-02 2022-06-07 Aligos Therapeutics Inc Compostos que têm como alvo prmt5
US11884672B2 (en) 2019-05-14 2024-01-30 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
AU2020283505A1 (en) * 2019-05-30 2021-12-23 Angex Pharmaceutical, Inc. Heterocyclic compounds as PRMT5 inhibitors
BR112021024999A2 (pt) * 2019-06-10 2022-01-25 Lupin Ltd Inibidores de prmt5
AU2020371295A1 (en) * 2019-10-22 2022-04-28 Lupin Limited Pharmaceutical combination of PRMT5 inhibitors
AU2020370281A1 (en) * 2019-10-25 2022-05-26 Accent Therapeutics, Inc. METTL3 modulators
US20230066014A1 (en) 2019-12-03 2023-03-02 Lupin Limited Substituted nucleoside analogs as prmt5 inhibitors
WO2021202480A1 (en) * 2020-04-01 2021-10-07 Aligos Therapeutics, Inc. Compounds targeting prmt5
CA3179189A1 (en) * 2020-04-03 2021-10-07 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
EP4188920A1 (en) 2020-07-31 2023-06-07 Tango Therapeutics, Inc. Piperidin-1-yl-n-pyrydine-3-yl-2-oxoacetamide derivatives useful for the treatment of mtap-deficient and/or mta-accumulating cancers
JP2024502886A (ja) 2021-01-19 2024-01-23 ルピン・リミテッド がんを処置及び/又は予防するためのsos1阻害薬の医薬組合せ
CN113234079B (zh) * 2021-04-30 2022-02-01 上海湃隆生物科技有限公司 用作prmt5抑制剂的核苷类似物

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004009574A1 (en) 2002-07-22 2004-01-29 Novartis Ag Synthesis of discodermolide
WO2005016878A2 (en) 2003-08-13 2005-02-24 Isis Pharmaceuticals, Inc. METHODS FOR THE PREPARATION OF 5-FLUORO-PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS
WO2006091905A1 (en) 2005-02-25 2006-08-31 Gilead Sciences, Inc. Bicyclo (3.1.0) hexane derivatives as antiviral compounds
EP2049490A1 (en) 2006-06-09 2009-04-22 Astra Zeneca AB N-(benzoyl)-o- [2- (pyridin- 2 -ylamino) ethyl]-l-tyrosine derivatives and related compounds as a5b1 antagonists for the treatment of solid tumors
CA2678248C (en) 2007-03-08 2016-06-28 Janssen Pharmaceutica Nv Quinolinone derivatives as parp and tank inhibitors
FR2926556B1 (fr) 2008-01-22 2010-02-19 Sanofi Aventis Derives de carboxamides n-azabicycliques, leur preparation et leur application en therapeutique
WO2010036213A1 (en) 2008-09-26 2010-04-01 Agency For Science, Technology And Research 3-deazaneplanocin derivatives
GB0922332D0 (en) 2009-12-22 2010-02-03 Isis Innovation Method of treatment and screening method
WO2011079236A1 (en) 2009-12-22 2011-06-30 The Ohio State University Research Foundation Compositions and methods for cancer detection and treatment
RU2560163C2 (ru) 2010-06-30 2015-08-20 Фуджифилм Корпорэйшн Новое производное никотинамида или его соль
WO2012037108A1 (en) 2010-09-13 2012-03-22 Glaxosmithkline Llc Aminoquinoline derivatives as antiviral agents
WO2012123298A1 (en) 2011-03-11 2012-09-20 F. Hoffmann-La Roche Ag Antiviral compounds
US9084794B2 (en) 2011-08-19 2015-07-21 Glaxosmithkline Intellectual Property (No. 2) Limited Fatty acid synthase inhibitors
AU2013250726B2 (en) * 2012-04-20 2017-01-05 Advinus Therapeutics Limited Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof
ES2624223T3 (es) 2012-06-08 2017-07-13 Gilead Sciences, Inc. Inhibidores macrocíclicos de los virus flaviviridae
WO2014008223A2 (en) 2012-07-03 2014-01-09 Glaxosmithkline Llc Fatty acid synthase inhibitors
EP2935240A1 (en) 2012-12-21 2015-10-28 Epizyme, Inc. Prmt5 inhibitors and uses thereof
JP2016505002A (ja) 2012-12-21 2016-02-18 エピザイム,インコーポレイティド ジヒドロイソキノリンまたはテトラヒドロイソキノリンを含有するprmt5阻害剤およびその使用
KR102173874B1 (ko) 2012-12-21 2020-11-05 에피자임, 인코포레이티드 테트라하이드로- 및 디하이드로-이소퀴놀린 prmt5 억제제 및 이의 용도
EP2935247B1 (en) 2012-12-21 2019-08-28 Epizyme, Inc. Prmt5 inhibitors and uses thereof
JP2016505001A (ja) 2012-12-21 2016-02-18 エピザイム,インコーポレイティド Prmt5阻害剤およびその使用
CA2897200C (en) 2013-01-14 2021-07-06 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
GB201302927D0 (en) 2013-02-20 2013-04-03 Cancer Therapeutics Crc Pty Ltd Compounds
US9856218B2 (en) 2013-03-15 2018-01-02 Ohio State Innovation Foundation Inhibitors of PRMT5 and methods of their use
KR20160076519A (ko) 2013-10-10 2016-06-30 아락세스 파마 엘엘씨 Kras g12c 억제제
WO2015177110A1 (en) 2014-05-22 2015-11-26 F. Hoffmann-La Roche Ag INDOLIN-2-ONE AND 1,3-DIHYDRO-PYRROLO[3,2-c]PYRIDIN-2-ONE DERIVATIVES
PE20170146A1 (es) 2014-06-25 2017-03-08 Glaxosmithkline Ip Dev Ltd Sales cristalinas de (s)-6-((1-acetilpiperidin-4-il)amino)-n-(3-(3,4-dihidroisoquinolin-2(1h)-il)-2-hidroxipropil)pirimidino-4-carboxamida
WO2015200680A2 (en) 2014-06-25 2015-12-30 Epizyme, Inc. Prmt5 inhibitors and uses thereof
EP3160466A4 (en) 2014-06-25 2017-12-27 Epizyme, Inc. Prmt5 inhibitors and uses thereof
WO2016022605A1 (en) 2014-08-04 2016-02-11 Epizyme, Inc. Prmt5 inhibitors and uses thereof
US10494376B2 (en) 2014-09-03 2019-12-03 Ctxt Pty. Ltd. Tetrahydroisoquinoline derived PRMT5-inhibitors
GB201415573D0 (en) 2014-09-03 2014-10-15 Cancer Therapeutics Crc Pty Ltd Compounds
WO2016034671A1 (en) 2014-09-03 2016-03-10 Ctxt Pty Ltd Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived prmt5-inhibitors
US20180010132A1 (en) 2014-09-11 2018-01-11 Novartis Ag Inhibition of prmt5 to treat mtap-deficiency-related diseases
JP6584521B2 (ja) 2015-02-24 2019-10-02 ファイザー・インク 抗がん剤として有用な置換ヌクレオシド誘導体
WO2016145150A2 (en) 2015-03-11 2016-09-15 The Broad Institute Inc. Selective treatment of prmt5 dependent cancer
AR104326A1 (es) 2015-05-04 2017-07-12 Lilly Co Eli Compuestos nucleósidos 5-sustituidos
TWI791251B (zh) 2015-08-26 2023-02-01 比利時商健生藥品公司 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物
EP3377481A1 (en) 2015-11-16 2018-09-26 Araxes Pharma LLC 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof
EA201990851A1 (ru) * 2017-02-24 2019-09-30 Янссен Фармацевтика Нв Новые аналоги карбануклеозида, замещенные моноциклической и бициклической кольцевой системой, для применения в качестве ингибиторов prmt5

Also Published As

Publication number Publication date
JP2021506793A (ja) 2021-02-22
US20220267339A1 (en) 2022-08-25
CU20200051A7 (es) 2021-03-11
CR20200263A (es) 2020-07-26
GEP20227359B (en) 2022-03-10
MX2020006181A (es) 2020-09-03
PT3724190T (pt) 2022-10-03
HUE059945T2 (hu) 2023-01-28
CU24621B1 (es) 2022-09-08
WO2019116302A1 (en) 2019-06-20
JP7282778B2 (ja) 2023-05-29
ZA202003528B (en) 2022-05-25
UA126349C2 (uk) 2022-09-21
US11952380B2 (en) 2024-04-09
US11459330B2 (en) 2022-10-04
PH12020550881A1 (en) 2021-04-05
ES2927860T3 (es) 2022-11-11
US20210163486A1 (en) 2021-06-03
CN111712498B (zh) 2023-09-29
EP3724190A1 (en) 2020-10-21
EP3724190B1 (en) 2022-07-06
CL2020001576A1 (es) 2020-11-06
CN111712498A (zh) 2020-09-25
HRP20221207T1 (hr) 2022-12-09
IL274936B2 (en) 2023-09-01
RS63623B1 (sr) 2022-10-31
PL3724190T3 (pl) 2022-10-31
IL274936B1 (en) 2023-05-01
CA3085259A1 (en) 2019-06-20
IL274936A (en) 2020-07-30
AU2018385664B2 (en) 2022-06-02
BR112020011746A2 (pt) 2020-11-17
SG11202004934QA (en) 2020-07-29
AU2018385664A1 (en) 2020-07-02
LT3724190T (lt) 2022-10-10
PE20211444A1 (es) 2021-08-05
KR20200098598A (ko) 2020-08-20

Similar Documents

Publication Publication Date Title
DK3724190T3 (da) Substituerede bicykliske heterocykliske forbindelser som PRMT5 inhibitorer
DK3704120T3 (da) Heterocykliske forbindelser som prmt5-inhibitorer
DK3442980T3 (da) Heterocykliske forbindelser som ret-kinase-hæmmere
DK3684767T3 (da) Heterocykliske forbindelser som pad-inhibitorer
DK3371190T3 (da) Heterocykliske forbindelser som pi3k-gamma-inhibitorer
DK3472167T3 (da) Heterocykliske forbindelser som immunomodulatorer
HK1249905A1 (zh) 作為lsd1抑制劑的雜環化合物
DK3436444T3 (da) Heterocyklisk forbindelse
DK3697785T3 (da) Imidazo-pyridine forbindelser som pad-inhibitorer
DK3377488T3 (da) Heterocykliske forbindelser som immunomodulatorer
ES2977657T3 (es) Compuestos de 6-azaindol
DK3298002T3 (da) Heterocykliske amider som kinasehæmmere
DK3324977T3 (da) Benzodiazepinderivater som rsv-inhibitorer
DK3302448T3 (da) Erstattede heterocyclylafledninger som cdk-inhibitore
DK3224256T3 (da) N-((het)arylmethyl)-heteroaryl-carboxamid-forbindelser som plasma kallikrein-inhibitorer
DK3768674T3 (da) Aminopyrimidinderivater som ctps1-hæmmere
MA47573A (fr) Inhibiteurs de dihydrobenzofurane glycosidase substitués
MA53287A (fr) Inhibiteurs de prmt5
DK3458460T3 (da) Imidazoler som histondemethylase-inhibitorer
DK3762368T3 (da) Aminopyrazindiolforbindelser som pi3k-y-inhibitorer
DK3544981T3 (da) Benzodiazoliumforbindelser som enac-inhibitorer
SG11202005112TA (en) Heterocyclic compounds as prmt5 inhibitors
DK3717488T3 (da) Substituerede furanopyrimidinforbindelser som pde1-inhibitorer
DK3630752T3 (da) Substituerede nitrogenholdige forbindelser
DK3790873T3 (da) 1h-indazol-3-carboxamidforbindelser som glycogensynthase-kinase-3-beta-inhibitorer